Research Compound Summary Compound: Retatrutide CAS Number: 2381089-83-2 Molecular Formula: C205H320N56O63S2 Purity: 99.71% (HPLC-UV verified) Third-Party Testing: Testides Analytical (independent lab, Toronto) COA Download: View Full COA (PDF) Report: DBAV-RETA-10-062726 Source: Canadian manufactured Shipping: Same-day from our BC facility Retatrutide peptide Canada: a novel triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously
Because it turns on three receptors at once, researchers use it to look at: Triple receptor (GLP-1 / GIP / glucagon) signaling Obesity and belly-fat models Appetite and food-intake studies Insulin sensitivity and blood-sugar control Energy burn (thermogenesis) through glucagon activation Heart and metabolic risk-factor studies Side-by-side tests with Tirzepatide and Semaglutide These uses come from published clinical and review research on this peptide and related incretin compounds
Many players also appreciate mobile-optimized interfaces, which should deliver fluid navigation, crisp lobbies, and streamlined cashier access on smaller screens without burying essential controls
5-7 Multiple studies have linked gut dysbiosis a change or imbalance in the diversity, composition and functions of the microbiota to reduced GLP-1 levels
Follow the titration schedule : Slow, gradual dose increases give your body time to adapt to each level of weight loss
Retatrutide is not yet FDA approved, but like many GLP-1 agonists such as Wegovy (semaglutide) and Mounjaro (tirzepatide), retatrutide will most likely be a weekly injection, delivered subcutaneously into the arm, thigh or stomach area in a self-inject pen
